ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Medicinova Inc

Medicinova Inc (MNOV)

2.17
-0.09
(-3.98%)
終了 12月12日 6:00AM
2.17
0.00
( 0.00% )
プレマーケット: 6:01PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
2.17
買値
2.00
売値
2.40
出来高
-
0.00 日の範囲 0.00
1.12 52 週間の範囲 2.55
時価総額
前日終値
2.17
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
71,238
発行済株式数
49,046,246
配当利回り
-
PER
-12.41
1 株当たり利益 (EPS)
-0.17
歳入
1M
純利益
-8.57M

Medicinova Inc について

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's cu... MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Medicinova Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker MNOV. The last closing price for Medicinova was US$2.17. Over the last year, Medicinova shares have traded in a share price range of US$ 1.12 to US$ 2.55.

Medicinova currently has 49,046,246 shares in issue. The market capitalisation of Medicinova is US$106.43 million. Medicinova has a price to earnings ratio (PE ratio) of -12.41.

MNOV 最新ニュース

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.09-3.982300884962.262.372.15431652.2835979CS
40.199.595959595961.982.481.7630122.11182165CS
120.5332.31707317071.642.551.49712382.13866774CS
260.77551.42.551.12537621.92256509CS
520.4727.64705882351.72.551.12495701.70284465CS
156-0.96-30.67092651763.133.221.12549712.15961604CS
260-5.71-72.4619289347.8813.251.122769456.39279589CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
PALIPalisade Bio Inc
US$ 2.90
(107.14%)
8.21M
AMPGAmplitech Group Inc
US$ 2.66
(37.82%)
8.3M
DBVTDBV Technologies SA
US$ 4.38
(33.13%)
2.41M
WHLRWheeler Real Estate Investment Trust Inc
US$ 5.91
(32.51%)
983.99k
ECBKECB Bancorp Inc
US$ 19.00
(25.99%)
104
PNBKPatriot National Bancorp Inc
US$ 1.08
(-58.78%)
13
SPGCSacks Parente Golf Inc
US$ 0.73
(-47.86%)
21.11k
AVGRAvinger Inc
US$ 0.432
(-47.32%)
21.98k
HEPAHepion Pharmaceuticals Inc
US$ 0.36
(-38.46%)
1
BCTXBriaCell Therapeutics Corporation
US$ 0.72
(-34.55%)
147.72k
AMPGAmplitech Group Inc
US$ 2.65
(37.31%)
8.31M
PALIPalisade Bio Inc
US$ 2.89
(106.43%)
8.21M
RGTIRigetti Computing Inc
US$ 6.85
(-7.18%)
2.76M
RZLVRezolve AI Ltd
US$ 2.21
(11.06%)
2.62M
DBVTDBV Technologies SA
US$ 4.39
(33.43%)
2.41M

MNOV Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock